Heart failure presents a major public health burden in China. With a rapidly rising urban population and a growing trend of unhealthy lifestyle, heart failure is expected to affect a sizeable population of the country. The treatment of acute heart failure (AHF) is dominated by older, cost-effective generic drugs; however, we expect the growing uptake of recently approved SGLT-2 inhibitors—canagliflozin (Janssen’s Invokana), dapagliflozin (AstraZeneca’s Farxiga), and empagliflozin (Eli Lilly’s Jardiance)—will lead the heart failure market to grow significantly during the forecast period. Nonetheless, a significant unmet need will continue to exist for patients with chronic heart failure with preserved ejection fraction (HF-pEF)—where treatment options are limited—representing an opportunity for drug developers in this space. In addition, the ongoing reforms in the regulatory and A&R landscape of China are expected to encourage MNCs to enter the heart failure market.
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific A&R environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.
Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and surveys with 50 cardiologists
Diagnosed prevalence of chronic heart failure and diagnosed incidence of acute heart failure in urban versus rural China; clinically relevant and market-relevant drug-treatable populations
10-year, annualized, drug-level sales and patient share of key heart failure therapies through 2031, based on primary and secondary market research to formulate bottom-up assumptions
Phase III/PR: 10 drugs; Phase II: 3 drugs; coverage of select preclinical and Phase I products